H. Lundbeck A/S

Pharmaceutical company focusing on the treatment of diseases of the central nervous system

The company was established as trading company in 1915 by Hans Lundbeck. The company went public in 1999. The shares are listed at the Copenhagen Stock Exchange (KFX). In July 2005, H. Lundbeck A/S and PAION Deutschland GmbH announced that they have entered into an exclusive partnership agreement regarding the development and marketing of PAION’s Phase III product (Desmoteplase) for stroke in Europe.

Claus Braestrup, President & CEO
Lars Bang, Executive VP, Supply Operations, Engineering and IT
Anders Götzsche, Executive VP, CFO
Stig Løkke Pedersen, Executive VP, Commercial Operations

Per Wold-Olsen, Chairman
Thorleif Krarup, Deputy Chairman
Kim Rosenville Christensen
Peter Kürstein
Mats Pettersson
Birgit Bundgaard Rosenmeier
William Watson
Jes Østergaard

Ottiliavej 9
2500 Copenhagen Valby
Denmark
Phone: +45-3630-1311
Fax: +45-3630-1940

Lundbeck produces pharmaceuticals for the treatment of central nervous system diseases, including depression, schizophrenia, Alzheimer’s, Parkinson’s and sleep disorders. R&D involves the entire drug discovery process from targeting patient needs and initial validation, through to the identification of suitable drug candidates and development of suitable drugs.

The company has also inlicensed products from international companies, including e.g. Forest Laboratories, Inc., Merck & Co., Inc., Teva Pharmaceutical Industries LTD, Cephalon, Inc. The company owns a large number of patents. A selection of recent patents is listed below.

The following section contains a selection of the company’s most relevant patents. For comprehensive patent information please refer to the espacenet databases.